Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | CTH | P32929 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963324 | 0.85 | CYP2D6 (0.40) | CYP2D6CHRM1HRH1KCNH2TRPM8 | |
| SCHEMBL22623952 | 0.80 | TRPM8 (0.39) | CYP2D6CHRM1HRH1KCNH2TRPM8 | |
| SCHEMBL442860 | 0.80 | TRPM8 (0.39) | CYP2D6CHRM1HRH1KCNH2TRPM8 | |
| SCHEMBL12363971 | 0.80 | TRPM8 (0.39) | CYP2D6CHRM1HRH1KCNH2TRPM8 | |
| SCHEMBL25211250 | 0.79 | TRPM8 (0.41) | CYP2D6CHRM1HRH1KCNH2TRPM8 | |
| SCHEMBL20738494 | 0.79 | CYP2D6 (0.38) | CYP2D6CHRM1HRH1KCNH2TRPM8 | |
| SCHEMBL20738495 | 0.79 | CYP2D6 (0.38) | CYP2D6CHRM1HRH1KCNH2TRPM8 | |
| SCHEMBL1858360 | 0.79 | TRPM8 (0.41) | CYP2D6CHRM1HRH1KCNH2TRPM8 | |
| SCHEMBL506640 | 0.79 | TRPM8 (0.41) | CYP2D6CHRM1HRH1KCNH2TRPM8 | |
| SCHEMBL6961060 | 0.79 | CYP2D6 (0.38) | CYP2D6CHRM1HRH1KCNH2TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056022-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11001579-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-11 | — | — | US | disclosed |
| US-20200397760-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | CYTEIR THERAPEUTICS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20190345151-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-11-14 | — | — | US | disclosed |
| US-10364239-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-07-30 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345151-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | CYP2D6 278/4885CHRM1 4844/4885HRH1 732/4885 |
| US-20200397760-A1 | METHODS OF USING RAD51 INHIBITORS FOR TREATMENT OF PANCREATIC CANCER | RAD51, MRE11, RAD52 | CYP2D6 4557/4885CHRM1 4871/4885HRH1 2338/4885 |
| US-11001579-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | CYP2D6 264/4885CHRM1 4848/4885HRH1 863/4885 |
| US-20220056022-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | CYP2D6 3798/4885CHRM1 4808/4885HRH1 1486/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | CYP2D6 1147/4885CHRM1 77/4885HRH1 316/4885 |
| US-10364239-B2 | Ferroportin inhibitors | HAMP, SLC40A1, HMOX1 | CYP2D6 276/4885CHRM1 4832/4885HRH1 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.